The role of panfungal polymerase chain reaction (PCR) assays for diagnosis of invasive fungal disease (IFD) is inadequately defined. We describe the use of an internal transcribed spacer 1 (ITS-1) region-directed panfungal PCR in this context at a tertiary referral transplant center. A retrospective review of patients at Alfred Health, Melbourne, Australia (2009 -2014 who had clinical samples referred for panfungal PCR testing was conducted. Baseline patient characteristics, antifungal drug history, fungal culture/histopathology, and radiology results were recorded. For bronchoalveolar lavage (BAL) fluid samples, identification of a fungus other than a Candida spp. was defined as a potential pathogen. Of 138 panfungal PCR tests (108 patients), 41 (30%) were positive for a fungal product. Ninety-seven percent (134/138) of specimens were from immunocompromised hosts. Thirteen percent (19/138) of panfungal PCR positive results were for potential pathogens and potential pathogens were detected more frequently in tissue as compared with BAL (12/13 vs. 6/26; P = .0001). No positive panfungal PCR results were obtained from CSF specimens. If histopathology examination was negative, panfungal PCR identified a potential pathogen in only 12% (11/94) of specimens. For the 20 culture negative/histopathology positive specimens, diagnosis of IFD to causative species level by panfungal PCR occurred in 35% (6/20). Sterile site specimens, in particular tissue, were more frequently panfungal PCR positive for potential pathogens than BAL. The utility of panfungal PCR appears greatest in tissue specimens, as an adjunct to histopathology to improve diagnostic sensitivity and 138
Introduction
Molecular methods such as those based on polymerase chain reaction (PCR) for the diagnosis of invasive fungal disease (IFD) are increasingly used in both immunosuppressed and nonimmunocompromised patient cohorts. However, currently no assay directed at detecting fungal nucleic acid is included in the EORTC/MSG consensus diagnostic criteria for IFD. 1, 2 Culture-based methods lack sensitivity and histopathology specificity for the causative fungus. 2 Clinical algorithms combining the different modalities continue to evolve. Panfungal PCR has a reported sensitivity and specificity of 51.7% and 97%, respectively, in microscopy negative samples in patients that meet the EORTC criteria for IFD. 3, 4 The sensitivity of panfungal PCR is higher for culture positive tissue samples where it approaches 98%.
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Rickerts et al. illustrated that from histopathologically proven IFD, panfungal PCR outperformed culture (96% vs. 63%, P = .006). 5 Nonetheless, an assessment of the clinical utility of panfungal PCR is limited by mixed patient, molecular PCR target and specimen studies, and variations in the "gold standard" comparator. Here, we describe the clinical utility of a panfungal PCR assay, described previously, which targets the internal transcribed spacer 1 (ITS1) region of the ribosomal DNA (rDNA), in a group of predominantly immunocompromised hosts with suspected IFD. 3 The rate of panfungal PCR positive results for specimen type, and its concordance with culture and histopathology were determined.
Material and methods

Study design and setting
We retrospectively reviewed the laboratory and medical record details of all patients that had panfungal PCR testing performed at Alfred Health between January 2009 and July 2014. Alfred Health is a tertiary referral 500-bed center, encompassing statewide (Victoria, Australia) Bone Marrow Transplant, Heart/Lung Transplant, Trauma, Burns, and human immunodeficiency virus (HIV) services. 
Study population
Panfungal PCR methodology
The panfungal PCR assay was performed at the Clinical Mycology Reference Laboratory, Westmead Hospital, Sydney. Briefly, the assay amplifies the internal transcribed spacer 1 (ITS1) region followed by DNA sequence analysis of the amplified PCR product for species identification. For paraffin embedded (PE) tissue sections, paraffin was removed prior to DNA extraction as previously described. Aspergillus GM testing were also performed as previously described.
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Study definitions
A sterile specimen included pleural fluid, tissue, and cerebrospinal fluid (CSF) samples and nonsterile specimens were BAL fluid. A potential pathogen was defined as a single panfungal PCR product that did not include Candida spp. from BAL. Radiology was considered consistent with an IFD as per previously published definitions for sinus, pulmonary, and central nervous system (CNS) infections.
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Target prophylaxis trough antifungal drug levels for voriconazole and posaconaozle were defined as 1-5.5 mg/l and > 0.7 mg/l, respectively. 9,10 All voriconazole and posaconazole levels were by high performance liquid chromatography (HPLC) as previously described. 11 Concordance between panfungal PCR, culture, and/or histopathology was defined as the same fungal genus identified.
Statistical analysis
Statistical analyses were performed using Stata 9.0 (Statacorp, TX, USA). Proportional outcomes were compared using the χ 2 test or Fisher's exact and continuous outcomes compared using the Student's t-test or Wilcoxon signedrank test as appropriate. A P-value of < .05 was statistically significant.
Results
Cohort characteristics and panfungal PCR positivity
Patient baseline characteristics are summarized in Table 1 . One hundred and thirty-eight specimens from 108 patients were tested using the panfungal PCR assay. Of these, 30% (41/138) were positive for a fungal PCR product ( Fig. 1 ). Eighteen percent (26/138) of specimens were positive for a single fungal species. Potential pathogens were identified in 13% (19/138) of specimens. From positive panfungal PCR specimens, potential pathogens were identified from sterile sites more commonly than from nonsterile sites (87%; 13/15 vs. 23%; 6/26 P = .0002) (Fig. 2) . Hematology patients contributed the majority of specimens (63%; 88/138). Thirty-eight percent (33/88) of specimens were from allogeneic transplant patients, with 78% (69/88) of hematology patients on antifungal therapy (prophylaxis or treatment) at the time of PCR testing and 76% (66/88) had radiological findings consistent with IFD. Panfungal PCR was positive in 30% (27/88) of hematology patients and 11% (10/88) for a potential pathogen. In these patients, potential pathogens were more commonly identified from tissue compared to BAL (100%; 6/6 vs. 15%; 3/19) (P = .0005) and from a sterile site compared to a nonsterile site (88%; 7/8 vs. 16%; 3/19, P = .0009). Ninety percent (9/10) of patients with a potential pathogen PCR positive result had therapeutic antifungal either started or continued following PCR result.
Panfungal PCR positivity for specimen type
Panfungal PCR was most commonly requested from BAL (46%; 63/138) and tissue (39%; 54/138) specimens (Table 2) . Potential pathogens occurred more frequently in tissue specimens as compared with BAL (12/13 vs. 6/26; P = .0001) ( Table 2) . No CSF (0/13) specimens were positive for potential fungal pathogens. Twenty-six percent (8/46) of fresh tissue samples (nonformalin/paraffin) specimens were panfungal PCR positive, compared with 12.5% (1/8) of paraffin-embedded tissue sections (P = .669).
Panfungal PCR results compared with histopathology and culture
In those specimens that were panfungal PCR positive for a potential pathogen, 26% (4/19) were also culture positive and 42% (8/19) histopathology positive. The number of positive fungal cultures and histopathology specimens in the setting of panfungal PCR positive and negative results are demonstrated in Figure 3 . The fungi cultured in the setting of panfungal PCR positive and negative results outlined in Box 1. Concordance with a potential pathogen PCR result and culture result was demonstrated in 80% (4/5) of specimens, compared with 75% (6/8) of histopathology and potential pathogen panfungal PCR results. In 25% (5/20) of patients that were histopathology positive but culture negative, the fungal species was determined by panfungal PCR. Panfungal PCR identified a potential pathogen from culture or histopathology negative specimens in 10% (13/123) and 12% (11/94), respectively. For specimens that were culture and histopathology negative, panfungal PCR was positive for a potential pathogen in 5% (5/88). The range of fungal species identified by panfungal PCR compared to fungal culture and histopathology can be found in Table 3 .
The effect of antifungal therapy on IFD diagnosis
Sixty-percent of (82/138) of patients were on antifungal therapy (prophylaxis or treatment) at the time of panfungal PCR testing. In those on triazole therapy, 57% (35/61) had a level above the defined prophylaxis target. In those on antifungal therapy, a potential pathogen was identified more from panfungal PCR than culture (65%; 15/23 vs. 33%; 1/3, P = .54). Histopathology was positive in 11 patients on antifungal therapy, 64% (7/11) with an identified fungal genus by histopathology (4 Mucormycosis; 3 Aspergillus spp.).
Treatment of patients with positive panfungal PCR results
Fifty-six percent (23/41) of patients with a positive panfungal PCR result received antifungal therapy for a presumed IFD following the panfungal PCR result. Sixty-nine percent (16/23) were on antifungal prophylaxis or treatment at time of PCR. Thirteen percent (3/23) had therapy changed from prophylaxis to definitive treatment, 56% had empirical treatment continued, and 30% (7/23) had treatment commenced in the setting of no prior antifungal therapy. More potential pathogens were treated from tissue compared to BAL specimens (75%; 9/12 vs. 50%; 3/6, P = .23). The potential pathogens treated for tissue and BAL specimens are highlighted in Table 4 .
Discussion
Despite the superiority of PCR methodology over culture and histology for IFD in tissue specimens, it remains absent from current EORTC consensus definitions. 2, 5 Growing interest in panfungal PCR for IFD diagnosis stems from inherent limitations of current "gold standard" methods of culture and histology. Chamilos et al. demonstrated that in 60% of histopathology-proven IFD, standard fungal culture was negative. 12 In many cases of deep mycoses, histopathology may be the only method of diagnosis, although it cannot identify the fungus genus or species. [13] [14] [15] The primary goal of this study was to examine the utility of panfungal PCR from a range of clinical specimens when compared with concurrent culture and histopathology testing. We demonstrated in our mixed population cohort that from tissue specimens the panfungal PCR outperformed culture and histopathology. In our cohort panfungal PCR identified a fungal pathogens in 14% of specimens from predominately immunosuppressed hosts with suspected IFD. We demonstrated greater than 80% concordance with panfungal PCR and culture positive results. The clinical utility of panfungal PCR was greatest from sterile sites, as 92% of panfungal PCR positive tissue results identified a pathogen. Conversely panfungal PCR testing on BAL was problematic, with over 80% of positive results identifying >2 PCR products or a yeast species. We also highlighted the ability of panfungal PCR to identify IFD when histopathology, and/or culture were negative. The only two discordant results identified were from nonsterile BAL specimens that cultured Aspergillus spp. These findings demonstrate that the utility of panfungal PCR is in increasing the diagnostic yield (in terms of sensitivity and specificity) when used in conjunction with culture and histopathology testing in tissue specimens. Based on our findings, we also recommend that BAL samples are not test by panfungal PCR.
Panfungal PCR was initially validated for tissue specimens, yet in many patients in this cohort, this assay was employed on BAL specimens. 3, [16] [17] [18] In studies that have examined panfungal PCR from tissue samples of patients with probable or proven IFD, a potential pathogen was identified in 20-50%. 13, 19 The emergence of species-specific
PCRs and other indirect measures of fungal invasion (i.e., GM, β-D-glucan) often means that panfungal PCR is employed in clinical scenarios only after multiple other investigations have yielded negative results. We suggest that the true utility of panfungal PCR is from tissue specimens and sterile site samples rather than BAL, in the setting of prior antifungal exposure. 3 Panfungal PCR results can be of significant value to the clinician especially in the immunocompromised host, providing rapid species-specific information that histopathology cannot provide. 5, 15 In our hematology cohort many on concurrent antifungal therapy, panfungal PCR on tissue samples outperformed culture and histopathology methods. In those on antifungals, a positive panfungal PCR was commonly associated with a change or continuation of definitive antifungal therapy. Our findings indicate that if an IFD is suspected in an at-risk hematology patient on antifungal therapy that a fresh tissue specimen should be obtained and sent for histology and concurrent panfungal PCR. A limitation of this study include is its single center retrospective design that limits extrapolation to all institutions. A further limitation is potential contamination resulting in false positive PCR results, in particular for the small number of paraffin embedded specimens. Although specimens Abbreviations: G2P, greater than or equal to 2 fungal PCR products referred for panfungal PCR originated from patients with suspected IFD and in 70% of cases radiology results were characteristic according to the EORTC, some specimens (i.e., CSF) may have been from patients with low probability IFD. Moreover, while chest high-resolution computed tomography (HRCT) has high sensitivity for IFD, it has a low relative specificity for fungal infection. 20, 21 An inability to identify a single fungal pathogen if >2 products were found on the panfungal PCR also limited the clinical significance of some results for the treating physicians. Increasing the yield of potential pathogens may be achieved by excluding samples where Candida spp. or Aspergillus spp. is cultured. In summary, we demonstrated in our single center that potential fungal pathogens identified by panfungal PCR results were detected more frequently from sterile sites and particularly tissue specimens. Panfungal PCR is a valuable adjunct to standard fungal culture and histopathology in sterile site specimens, especially in those on antifungal therapy. Further studies examining the role panfungal PCR in CSF, pleural fluid, and BAL specimens, particularly in those with triazole exposure, are required. Based on the results of this study, we would recommend that panfungal PCR is only used in tissue samples obtained from sterile sites. Table 3 . Fungal species identified by panfungal PCR assay according to concurrent positive results by culture or histopathology.
